ES2038579T3 - Celulas de levadura del genero schwanniomyces. - Google Patents

Celulas de levadura del genero schwanniomyces.

Info

Publication number
ES2038579T3
ES2038579T3 ES89107780T ES89107780T ES2038579T3 ES 2038579 T3 ES2038579 T3 ES 2038579T3 ES 89107780 T ES89107780 T ES 89107780T ES 89107780 T ES89107780 T ES 89107780T ES 2038579 T3 ES2038579 T3 ES 2038579T3
Authority
ES
Spain
Prior art keywords
dna sequence
yeast cells
genus schwanniomyces
expression
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89107780T
Other languages
English (en)
Other versions
ES2038579T1 (es
Inventor
Cornelius P Prof Dr Hollenberg
Alexander Dr Strasser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynavax GmbH
Original Assignee
Rhein Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Biotech GmbH filed Critical Rhein Biotech GmbH
Publication of ES2038579T1 publication Critical patent/ES2038579T1/es
Application granted granted Critical
Publication of ES2038579T3 publication Critical patent/ES2038579T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA CELULA DE FERMENTACION DEL GENERO "SCHWANNIOMYCES" EN DONDE LA MENCIONADA CELULA CONTIENE AL MENOS UN GRUPO DE EXPRESION QUE CONSTA DE: A) UNA PRIMERA SECUENCIA DE DNA QUE SIRVE COMO REGULADOR B) OPCIONALMENTE UNA SEGUNDA SECUENCIA DE DNA QUE CODIFICA UN PEPTIDO DE SEÑAL C) UNA TERCERA SECUENCIA DE DNA QUE CODIFICA UNA PROTEINA EXTERIOR D) OPCIONALMENTE UNA CUARTA SECUENCIA DE DNA QUE SIRVE COMO TERMINADOR. PREFERENTEMENTE PARA ESTA INVENCION, LA PRIMERA, SEGUNDA Y/O CUARTA SECUENCIA DE DNA SE DERIVAN DE LOS GENES QUE CODIFICAN ENZIMAS AMILOLITICAS DE CELULAS DE FERMENTACION DEL GENERO "SCHWANNIOMYCES". EL USO DE ESTAS SECUENCIAS FUNCIONALES EN UN GRUPO DE EXPRESION PROPORCIONA UNA EXPRESION EFICAZ DE GENES EXTERIORES EN CELULAS DE FERMENTACION SEGUN LA PRESENTE INVENCION Y, ADEMAS, PROPORCIONA UN SISTEMA DE SECRECION EFICAZ DEL PRODUCTO DE EXPRESION EN EL MEDIO.
ES89107780T 1989-04-28 1989-04-28 Celulas de levadura del genero schwanniomyces. Expired - Lifetime ES2038579T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP89107780A EP0394538B1 (en) 1989-04-28 1989-04-28 A yeast cell of the genus schwanniomyces

Publications (2)

Publication Number Publication Date
ES2038579T1 ES2038579T1 (es) 1993-08-01
ES2038579T3 true ES2038579T3 (es) 1997-02-16

Family

ID=8201308

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89107780T Expired - Lifetime ES2038579T3 (es) 1989-04-28 1989-04-28 Celulas de levadura del genero schwanniomyces.

Country Status (7)

Country Link
EP (1) EP0394538B1 (es)
JP (1) JPH03143385A (es)
AT (1) ATE144281T1 (es)
CA (1) CA2015077C (es)
DE (2) DE394538T1 (es)
ES (1) ES2038579T3 (es)
GR (2) GR910300058T1 (es)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333127T2 (de) 1992-06-03 2004-05-06 Genentech, Inc., South San Francisco Varianten des Gewebeplasminogenaktivators mit verbesserter therapeutischer Wirkung
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
EP0885299B1 (en) 1996-01-08 2005-10-26 Genentech, Inc. Ob receptor and ligands
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
US6387657B1 (en) 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
DE69840051D1 (de) 1997-10-29 2008-11-06 Genentech Inc Durch wnt-1 induzierbare gene
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1666494A1 (en) 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897944B1 (en) 1999-12-23 2011-08-10 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
DE60137829D1 (de) 2000-01-13 2009-04-16 Genentech Inc Menschliche stra6 polypeptide
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2709771A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
WO2005010044A2 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
BR0212070A (pt) 2001-08-29 2004-09-28 Genentech Inc ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
ES2431929T3 (es) 2001-09-18 2013-11-28 Genentech, Inc. Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
MXPA04012243A (es) 2002-06-07 2005-02-25 Genentech Inc Composiciones y metodos para l diagnostico y tratamiento de tumores.
EP1572130A4 (en) 2002-07-08 2008-07-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNEAL DISEASES
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2004024072A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2004024862A2 (en) * 2002-09-13 2004-03-25 Wockhardt Limited Yeast protein expression secretion system
EP1578364A4 (en) 2002-09-16 2011-06-08 Genentech Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP1576137A4 (en) 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
JP2011516026A (ja) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PL2295073T3 (pl) 2003-11-17 2014-09-30 Genentech Inc Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1962584A2 (en) 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AU2007233263A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
CN101437536A (zh) 2006-03-23 2009-05-20 诺华有限公司 抗肿瘤细胞抗原抗体治疗
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
BRPI0716680A2 (pt) 2006-11-02 2013-09-24 Daniel J Capon "composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo"
US7875431B2 (en) 2007-02-22 2011-01-25 Genentech, Inc. Methods for detecting inflammatory bowel disease
HUE037162T2 (hu) 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EP2274334A2 (en) 2008-03-28 2011-01-19 Sea Lane Biotechnologies,llc. Neutralizing molecules to viral antigens
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
CA2757382A1 (en) 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
DK2440241T3 (en) 2009-06-08 2017-10-02 Amunix Operating Inc GROWTH HORMON POLYPEPTIDES AND PROCEDURES FOR PREPARING AND USING THEREOF
CN102656266B (zh) 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
AR078986A1 (es) 2009-11-12 2011-12-14 Genentech Inc Un metodo para promover la densidad de espinas dendriticas
PE20121584A1 (es) 2009-11-30 2012-11-29 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
NZ601293A (en) 2010-02-23 2014-10-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
KR101768118B1 (ko) 2010-06-25 2017-08-14 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 기도 감염의 치료를 위한 방법 및 약학 조성물
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
WO2012036884A2 (en) 2010-09-15 2012-03-22 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
DK2968495T3 (da) 2013-03-15 2019-10-14 Daniel J Capon Hybrid immunoglobulin indeholdende en ikke-peptid-bro
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
SI3116486T1 (sl) 2014-03-14 2020-07-31 Biomolecular Holdings Llc Hibridni imunoglobulin, ki vsebuje nepeptidilno vezavo
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
CN107653261A (zh) * 2017-10-19 2018-02-02 昆明理工大学 利用啤酒酵母MF‑α介导重组蛋白分泌的植物表达载体
WO2019089544A1 (en) 2017-11-01 2019-05-09 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
US12084489B2 (en) 2018-05-02 2024-09-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
WO2021164744A1 (en) 2020-02-19 2021-08-26 Evive Biotechnology (Shanghai) Ltd Methods for treating graft versus host disease
WO2021211493A1 (en) 2020-04-15 2021-10-21 Genentech, Inc. Copper loss mitigation
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82935A0 (en) * 1986-08-12 1987-12-20 Phillips Petroleum Co Secretion of heterologous proteins from yeast
EP0260404B1 (en) * 1986-08-21 1995-05-31 VAN DEN BERG, Robert Amylolytic enzymes producing microorganisms constructed by recombinant DNA technology and their use for fermentation processes
EP0257115A1 (en) * 1986-08-21 1988-03-02 Heineken Technisch Beheer B.V. Amylolytic enzyme producing microorganisms, constructed by recombinant DNA technology, and their use in fermentation processes

Also Published As

Publication number Publication date
GR910300058T1 (en) 1991-11-15
ATE144281T1 (de) 1996-11-15
DE68927344T2 (de) 1997-02-20
EP0394538A1 (en) 1990-10-31
ES2038579T1 (es) 1993-08-01
DE68927344D1 (de) 1996-11-21
DE394538T1 (de) 1991-04-11
JPH03143385A (ja) 1991-06-18
CA2015077A1 (en) 1990-10-28
GR3022124T3 (en) 1997-03-31
EP0394538B1 (en) 1996-10-16
CA2015077C (en) 2000-07-25

Similar Documents

Publication Publication Date Title
ATE144281T1 (de) Hefezellen der gattung-schwanniomyces
DK82293D0 (da) Normalt sporulerende bacillus uden evne til at udskille subtilisin eller neutral protease, kulturer deraf og fremgangsmaade til fremstilling af heterologe proteiner dermed
ATE64151T1 (de) Rekombinante immunoglobulin-praeparate, verfahren zu ihrer herstellung, dna-sequenzen, expressionsvektoren und rekombinante wirkzellen hierfuer.
NO179106C (no) Fremgangsmåte for fremstilling av og ekspresjonssystem som koder for og kan uttrykke et rekombinant proteinkompleks med humanfaktor V111:C-aktivitet
DE69333766D1 (de) Herstellung von phytat-degradierenden enzymen in trichoderma
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
ES8703930A1 (es) Procedimiento de preparar hirudina y analogos a partir de levadura
ATE79403T1 (de) Herstellung von thrombin-inhibitoren.
WO1990003435A3 (fr) Acide nucleique codant pour l'enzyme de conversion de l'angiotensine (eca) humaine, et ses applications, notamment pour le diagnostic in vitro de l'hypertension arterielle
AU8258591A (en) Human mk gene and protein sequence
AU621810B2 (en) Amylolytic enzymes producing microorganisms, constructed by recombinant DNA technology and their use for fermentation processes
NO984491L (no) SCF-analogpreparater og fremgangsmÕte for fremstilling av disse
NO911557D0 (no) Fremgangsmaate for fremstilling av fremmedproteiner i streptomyceter.
EP0605073A3 (en) Molecular cloning and expression of neutral protease genes.
ES2171563T3 (es) Nueva familia de inhibidores de proteasas, y otras sustancias de actividad biologica.
ATE316138T1 (de) Rekombinante expression von s-layer-proteinen
DE3782560D1 (de) Hefestaemme zur expression fremder gene.
AU2253288A (en) Expression vectors for the synthesis of proteins and plasmid replicons and sequence cassettes for use in constructing such vectors
RU97103147A (ru) Днк-последовательности, кодирующие человеческие протеины тх и ту, родственные конвергирующему интерлейкин-1-бета ферменту
DE3682166D1 (de) Herstellung von insektizidprotein von bacillus thuringiensis subsp. aizawai ipl durch die expression von insektizidprotein-gen in wirtszellen.
ES2101694T3 (es) Expresion de edulcorantes proteinicos en levadura.
AU5239290A (en) Purification of c.pseudotuberculosis toxin, and cloning and expression of toxin gene
IT8521507A0 (it) Vettore di clonaggio, molecole di dna ricombinante, ceppi di bacillus subtilis trasformati con dette molecole e metodi per l'espressione di geni eterologhi e produzione e secrezione di proteine codificate da detti geni.
IT1262997B (it) Composto proteico e sequenze nucleotidiche codificanti per esso.
NO944878L (no) Modifisert Kluyveromyces-gjær, dens fremstilling og anvendelse

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 394538

Country of ref document: ES